Nebivolol Sandoz (Nebivolol)

Nebivolol selectively blocks β1‑adrenergic receptors in the heart, decreasing heart rate and contractile force. At the same time, it stimulates endothelial nitric‑oxide synthase, producing nitric oxide that relaxes vascular smooth muscle. This dual action results in reduced peripheral resistance and lower arterial pressure.

The specific dose of nebivolol is determined by the prescribing clinician based on the individual’s medical condition, response to therapy, and any concomitant medications. Dosage adjustments may be required for patients with renal or hepatic impairment, and the prescriber will provide the appropriate regimen.

Safety data for nebivolol in pregnancy and lactation are limited, and the product is classified as having an unknown pregnancy category. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To place an order, submit an enquiry on the Nebivolol Sandoz product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Nebivolol is a third‑generation, β1‑selective blocker with additional nitric‑oxide‑mediated vasodilatory properties, which can result in fewer metabolic side effects compared with older non‑selective beta‑blockers. Its dual mechanism may offer better blood‑pressure control and improved tolerability in some patients, though individual response varies.

Store Nebivolol Sandoz at room temperature, below 25 °C, in the original packaging to protect it from moisture and light. Keep the container tightly closed and out of reach of children. Do not store in a bathroom or other humid environment.

Nebivolol Sandoz is taken orally, usually once daily, with or without food as directed by the prescriber. The tablet should be swallowed whole with a glass of water and not chewed or crushed unless specifically instructed.

Serious adverse events include severe bradycardia, symptomatic hypotension, heart block, bronchospasm in patients with reactive airway disease, and rare allergic reactions such as angioedema. Patients should seek immediate medical attention if they experience fainting, rapid weight gain, swelling of the face or throat, or persistent shortness of breath.

Nebivolol is contraindicated in patients with known hypersensitivity to nebivolol or any component of the formulation, in those with severe sinus bradycardia, second‑ or third‑degree atrioventricular block without a pacemaker, and in individuals with uncompensated heart failure or cardiogenic shock. Caution is also advised for patients with asthma, COPD, or significant hepatic impairment.